Business

Biotech, pharma, and money in science

Sean Parker
Biotech

Sean Parker, billionaire and philanthropist, gets an immunotherapy company off the ground

By Adam Feuerstein

DNA Strand - Abstract
Biotech

Blueprint and Ipsen to work together on treatment for ultra-rare genetic disorder

By Jonathan Saltzman — Boston Globe

Alexion Pharmaceuticals Inc
Biotech

Alexion acquiring Achillion to expand reach into rare, immune-related disease

By Adam Feuerstein

Test tubes and pipette
Biotech

UCB’s $2.5 billion purchase of Ra Pharma underscores immunology focus

By Jonathan Saltzman — Boston Globe

Biotech

Archived chat: An online discussion about the Q4 biotech scorecard

By Adam Feuerstein

colored DNA sequencing
Business

Illumina confronts the innovator’s dilemma

By Matthew Herper

Adam's Take

A cancer company has misled investors repeatedly about its drug. It’s time for some truth-telling

By Adam Feuerstein

Sarepta - Cambridge -AP
Biotech

Sarepta gene therapy improves muscle function for patients with rare limb-girdle disease

By Adam Feuerstein

Trump drug prices
Pharmalot

White House insists drug prices are falling, but critics say its report is flawed

By Ed Silverman

TUFTS - Sackler
Business

Top colleges took in at least $60 million from family that owns Purdue Pharma as opioid lawsuits piled up

By Associated Press

LabCentral Rendering
Biotech

Biotech incubator LabCentral to double its space in Boston

By Jonathan Saltzman — Boston Globe

Scorecard
Biotech

The biotech scorecard for the fourth quarter: 13 stock-moving events to watch

By Adam Feuerstein

Heart ultrasound GIF
Health

An AI startup, led by 23andMe veteran Andy Page, tries to take better pictures of the heart

By Matthew Herper

Vertex Pharmaceuticals Inc. building
Biotech

Vertex takes on Huntington’s disease in deal with Ribometrix

By Jonathan Saltzman — Boston Globe

human colon cancer cells
Biotech

Amgen’s KRAS-blocking drug shows minimal effect in colon cancer patients

By Adam Feuerstein

Bayer headquarters
Business

Bayer to invest in Boston lab focused on chronic lung conditions

By Jonathan Saltzman — Boston Globe

Ginkgo Bioworks 06
Biotech

Ginkgo Bioworks scores an eye-popping valuation with latest fundraise

By Jonathan Saltzman — Boston Globe

Business

Martin Shkreli’s drug company is losing money — and its salesforce feels cheated

By Adam Feuerstein

Christopher Reeve and his wife Dana
Business

Reeve Foundation to invest in paralysis-treatment companies, as more nonprofits act like VCs

By Rebecca Robbins

CVS/Aetna
Business

Former CVS head’s gift will bolster neuroscience research at University of Rhode Island

By Edward Fitzpatrick — Boston Globe

Health Tech

Former Athenahealth CEO Jonathan Bush joins health care startup

By Jon Chesto — Boston Globe

Purdue Pharma headquarters
Business

Purdue Pharma filed for bankruptcy. What does it mean for lawsuits against the opioid manufacturer?

By Andrew Joseph

Purdue Pharma headquarters
Business

Purdue Pharma, maker of OxyContin and other drugs, files for bankruptcy

By Andrew Joseph

Peanuts on red background
Biotech

FDA advisory panel recommends approval of Aimmune peanut allergy therapy

By Adam Feuerstein

MODERNA - Norwood facility
Biotech

With some safety caveats, new Moderna data show mRNA can teach the body to make its own medicine

By Adam Feuerstein

Joel S. Marcus
Pharmalot

Judge dismisses real estate tycoon’s lawsuit against his son

By Jonathan Saltzman — Boston Globe

Biotech

Did a biotech exec crib a New Yorker cartoon?

By Jonathan Saltzman — Boston Globe

Play
Business

Watch: Direct-to-consumer drug advertising, explained

By Damian Garde

Peanut butter
Biotech

7 things to know about Aimmune’s peanut allergy therapy ahead of a pivotal FDA meeting

By Adam Feuerstein

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy